{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
First approved in 1961
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
ETRYPTAMINE (MONASE®), similar to the hallucinogenic tryptamines, is an inhibitor of monoamine oxidase, introduced for use as an antidepressant. It was withdrawn from the market due to problems with agranulocytosis and other side effects. However, it's activity is still under scientific investigation.
Status:
First approved in 1961
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
ETRYPTAMINE (MONASE®), similar to the hallucinogenic tryptamines, is an inhibitor of monoamine oxidase, introduced for use as an antidepressant. It was withdrawn from the market due to problems with agranulocytosis and other side effects. However, it's activity is still under scientific investigation.
Status:
US Previously Marketed
Source:
DEPROL BENACTYZINE by WALLACE
(1961)
Source URL:
First approved in 1957
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Benactyzine, an anticholinergic drug, had been used as an antidepressant in the treatment of depression and associated anxiety. It is no longer used in medicine due to its ineffectiveness but is widely used in scientific research. Benactyzine is a muscarinic antagonist which also inhibits the nicotinic acetylcholine receptor.
Status:
US Previously Marketed
Source:
Marsilid Phosphate by Hoffmann-La Roche
(1955)
Source URL:
First approved in 1955
Source:
Marsilid Phosphate by Hoffmann-La Roche
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAO) of the hydrazine class. It was originally developed for the treatment of Tuberculosis, but in 1952, its antidepressant properties were discovered when researchers noted that patients given isoniazid became inappropriately happy. Iproniazid is no longer clinically prescribed and has been withdrawn due to incidences of hepatotoxicity.
Status:
Possibly Marketed Outside US
Source:
RUBINORM by Meltzer, H.L.|Fieve, R.R.
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).
Status:
Possibly Marketed Outside US
Source:
RUBINORM by Meltzer, H.L.|Fieve, R.R.
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).
Status:
Possibly Marketed Outside US
Source:
RUBINORM by Meltzer, H.L.|Fieve, R.R.
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).
Status:
Possibly Marketed Outside US
Source:
RUBINORM by Meltzer, H.L.|Fieve, R.R.
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).
Status:
Possibly Marketed Outside US
Source:
RUBINORM by Meltzer, H.L.|Fieve, R.R.
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rubidium chloride is an inorganic compound with the formula RbCl. It appears to be nontoxic and therapeutically effective in several types of depressive disorders. This drug develops his action on dopaminergic stimulation reducing the depressive pattern. Also radioactive rubidium-82 chloride is used as diagnostic agent in positron emission tomography (PET).
Status:
Possibly Marketed Outside US
Source:
NCT04126135: Phase 4 Interventional Completed Nicotine Addiction
(2022)
Source URL:
First approved in 2018
Source:
Bei Ling Tong Bao Er Zheng Yuan Antibacterial Creams by Jilin Mancaotang Health Management Group Co Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Cytisine ( aka baptitoxine and sophorine) is a naturally occurring alkaloid that can be found in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been found to be clinically superior to nicotine replacement therapy for the cessation of smoking. It is available in Eastern Europe under the brand names Tabex and Desmoxan and in Canada under the brand name Cravv. However certain undesirable side effects exist, Cytisine can interfere with breathing and cause death (LD50 i.v., in mice, is about 2 mg/kg) and Cytisine is also teratogenic. Cytosine is an α4β2 nicotinic Acetylcholine receptor agonist. In addition to clinical use as a smoking cessation aid, It has demonstrated anti-depressant effects in mice.